(Q37012084)

17 August 2017

1 reference

title

GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer (English)

1 reference

17 August 2017

1 reference

1 reference

James E Ward

1

1 reference

17 August 2017

Douglas G McNeel

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

Expert Opinion on Biological Therapy

17 August 2017

published in

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

12

1 reference

17 August 2017

page(s)

1893-1902

1 reference

17 August 2017

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

Phase II trial of GM-CSF in advanced prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

VEGF as a mediator of tumor-associated immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

GM-CSF gene-transduced tumor vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

Cellular immunotherapies for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

Prostate cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1893

10.1517/14712598.7.12.1893

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference